Ryan Kieser
YOU?
Author Swipe
View article: 1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC) Open
Background Immune checkpoint inhibitor (ICI)-based regimens including pembrolizumab/axitinib (P/A), nivolumab/cabozantinib (N/C), and nivolumab/ipilimumab (N/I) have improved outcomes in patients with RCC. While immune related adverse even…
View article: 451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab
451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab Open
Background The therapeutic landscape of unresectable Hepatocellular carcinoma (uHCC) continues to evolve. Atezolizumab, an anti-programmed cell death ligand 1 (PD-1) immune checkpoint inhibitor (ICI) in combination with bevacizumab have su…
View article: 1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC) Open
Background While infections are a known cause of morbidity and mortality in those receiving chemotherapy, the burden of infections in the ICI era is seldom explored. This analysis aimed to assess incidence of infections and risk factors in…
View article: 480 Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies
480 Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies Open
Background Immune checkpoint inhibitor (ICI) therapy has improved outcomes in patients with NSCLC, particularly with the programmed death-1 inhibitor pembrolizumab. However, this therapy is not benign and while immune related toxicities ar…
View article: Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients
Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients Open
In the cancer population, patients diagnosed with venous thromboembolism (VTE) are considered to have a threefold increased risk of mortality compared with those without VTE. With the advent of modern computed tomography (CT), the rate of …
View article: Standardizing Opioid Prescribing Practices for Cancer-Related Pain Via a Novel Interactive Documentation Template at a Public Hospital
Standardizing Opioid Prescribing Practices for Cancer-Related Pain Via a Novel Interactive Documentation Template at a Public Hospital Open
PURPOSE: Opioid misuse during cancer pain management places patients at risk for harm and physicians for legal liability. Identifying and monitoring patients who are at risk is challenging given the lack of validated clinical tools and evi…